FCGR2A and inflammatory bowel disease: In case of bevacizumab, FcγR mediated effector functions are reported not to play a biological role, whereas for infliximab, antibody-dependent cell-mediated cytotoxicity (ADCC) may contribute in the activity in inflammatory bowel disease.